

Stemming from the collaborative efforts of the Canadian Cancer Survivor Network, the Save Your Skin Foundation and the Schizophrenia Society of Ontario, this <u>second annual national patient education</u>, <u>awareness and mobilization summit</u> will offer an opportunity for patients, patient advocates, caregivers and their groups from all disease and disability areas to come together. Over two days, we will examine how we can meaningfully participate in and influence regulatory, public and private drug pricing processes in Canada. In addition to hearing recommendations from key stakeholders to inform and guide our discussions, we will review and renew working committee composition and strategic objectives, and continue to explore tactics to influence drug pricing policy in Canada.

Registration is now open for the 2nd Annual Drug Pricing Policy Summit!

The Summit will take place on November 15-16, 2017 at the Japanese Canadian Cultural Centre, 6 Garamond Crt., Toronto, ON (free parking available on site).

Registration is free. Breakfast, lunch and health breaks will be provided. Limited funding is available for patient groups from outside Toronto. Contact Antonella Scali (ascali@schizophrenia.on.ca) for additional details.

Please register at: <u>https://www.eventbrite.ca/e/drug-pricing-in-canada-mobilizing-patients-to-action-tickets-37731814874</u>

Confirmed Speakers Include:

- Alan Birch, Drug Access Facilitator, North York General Hospital
- Andre Dias, Head of Regulatory and Commercial, Myia Labs
- Fred Horne, Principal, Horne and Associates, and Senior Advisor, 3 Sixty Public Affairs, and Former Minister of Health, Alberta (2011-2014)
- Ilias Iliopoulos, Associate Director, Patient Access Ontario and Federal, Merck Canada Inc.
- Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance Office
- Joan Weir, Director, Health and Disability Policy, Canadian Life and Health Insurance Association
- Dr. Kim Critchley, Deputy Minister, Health and Wellness, Province of Prince Edward Island
- Kim Furlong, Director, Federal Government Affairs and Policy, Amgen Canada
- Linda Wilhelm, President, Canadian Arthritis Patient Alliance
- Martine Elias, Director Access, Advocacy and Community Relations, Myeloma Canada
- Michele Chadwick, Lead, Regulatory Review of Drugs and Devices, Health Canada
- Mark Legault, Director, Market Access & Strategic Pricing, Pfizer Canada
- Noel MacKay, Principal Consultant, National Benefits, The Williamson Group
- Phil Upshall, Mood Disorders Society of Canada
- Dr. Sandy Sehdev, Medical Oncologist at The Ottawa Hospital Cancer Centre
- Tanya Potashnik, Director, Policy & Economic Analysis Branch, Patented Medicine Prices Review Board
- Terri Lohnes, Vice President and Practice Lead, Public Sector, Healthcare and Not-For-Profit Group, Optimus ISBR and representatives of :
- The Canadian Agency for Drugs and Technologies in Health (CADTH)
- Private industry members

AGENDA DAY 1 - WEDNESDAY NOVEMBER 15, 2017

- 8.30-9.00 Breakfast and registration
- 9.00-9.10 Welcome Address
- 9.10-9.20 Overview of Summit Agenda
- 9.20-10.40 Keynote Panel: Light at the end of the Tunnel: Value Based Health Outcomes
- 10.40-10.50 Patient Perspectives: So what does this really mean to patients?
- 10.50-11.00 Q&A
- 11.00-11.15 BREAK
- 11.15-11.45 Working Committees: What have we been up to since last year?
- 11.45-12.15 Patient Roundtable Discussion

12.15-13.15 LUNCH

- 13.15-14.15 PANEL 2: What's Hot and What's Not Under "Sunny Ways"?
- 14.15-14.25 Patient Perspectives: What does this mean to patient access?
- 14.25-14.35 Q&A
- 14.35-14.50 BREAK
- 14.50-15.50 PANEL 3: Not such "Sunny Ways" for Those Who Write the Cheques?
- 15.50-16.00 Patient Perspectives: Sunny or rainy days for patient access?
- 16.00-16.10 Q&A
- 16.10-16.40 Patient Roundtable Discussion
- 16.40-17.00 Wrap-up of Day 1

AGENDA DAY 2 - THURSDAY NOVEMBER 16, 2017

- 8.30-9.00 Breakfast and registration
- 9.00-9.10 Welcome Address Day 2
- 9.10-10.10 PANEL 4: Creative Ideas to Manage Cost and Sustainability
- 10.10-10.20 Patient Perspectives
- 10.20-10.30 Q&A
- 10.30-10.45 BREAK
- 10.45-12.00 PANEL 5: Implications for the Pharmaceutical Industry in Canada
- 12.00-12.10 Patient Perspectives: What do these changes mean for access?

12.10-12.20 Q&A

12.20-13.15 LUNCH

- 13.15-14.00 PANEL 6: How do We Get There from Here? Words to the Wise
- 14.00-14.10 Q&A
- 14.10-14.25 Observer High Level Perspectives and Observations

14.25-14.40 BREAK

- 14.40-15.40 Group Work
- 15.40-16.35 Priority Setting and Next Steps (Draft 2017-2018 Action plan review and Committee sign up)
- 16.35-16.45 Summit Wrap Up and Evaluation

We look forward to seeing you at the Summit!